Search Result
Results for "
caninized
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P99483
-
AT 004; VT 007
|
CD20
|
Cancer
|
Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .
|
-
-
- HY-P99301
-
Anti-Canine IL31 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
|
-
-
- HY-112542
-
CL-287088; LL-F28249 α
|
Parasite
Antibiotic
|
Infection
|
Nemadectin (CL-287088), an orally active broad-spectrum endectocide, is highly efficacious against natural infections of all the major canine gastrointestinal helminthes. Anthelmintic activity .
|
-
-
- HY-P99606
-
ZTS-00521426
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .
|
-
-
- HY-P99641
-
|
PD-1/PD-L1
|
Cancer
|
Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .
|
-
-
- HY-107917
-
DOCP
|
Mineralocorticoid Receptor
|
Endocrinology
|
Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of Desoxycorticosterone. Desoxycorticosterone pivalate is used for the management of canine hypoadrenocorticism .
|
-
-
- HY-138502
-
|
Parasite
|
Infection
|
Melarsomine is a trivalent arsenical compound used as an adulticide. Melarsomine can be used for the reserach of canine heartworm disease and other helminth infections .
|
-
-
- HY-138502A
-
|
Parasite
|
Infection
|
Melarsomine dihydrochloride is a trivalent arsenical compound used as an adulticide. Melarsomine dihydrochloride can be used for the reserach of canine heartworm disease and other helminth infections .
|
-
-
- HY-150092
-
|
Drug Metabolite
|
Cardiovascular Disease
|
8(S),9(R)-EET is an eicosanoid product of Arachidonic acid (AA; HY-109590) by cytochromes P450. 8(S),9(R)-EET dilates canine epicardial arterioles in a concentration-dependent manner with an EC50 value of 121 nM .
|
-
-
- HY-17623C
-
(R)-CJ-12420; (R)-RQ-00000004
|
Proton Pump
|
Metabolic Disease
|
(R)-Tegoprazan (example 3), a benzimidazole derivative, is a potent kidney H +/K +-ATPase inhibitor with an IC50 of 98 nM of canine kidney Na +/K +-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .
|
-
-
- HY-P99297
-
ZTS-00508841
|
Trk Receptor
|
Inflammation/Immunology
|
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
|
-
-
- HY-101597
-
|
Apoptosis
|
Cancer
|
NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC50=3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP .
|
-
-
- HY-107416
-
U-57908
|
Acyltransferase
mAChR
COX
Phospholipase
|
Neurological Disease
Metabolic Disease
|
RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC50 of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC50 of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC) .
|
-
-
- HY-P1784
-
|
Secretin Receptor
|
Endocrinology
|
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .
|
-
-
- HY-P1541
-
Motilin (canine)
|
Motilin Receptor
|
Metabolic Disease
|
Motilin, canine is a 22-amino acid peptide. Motilin is a potent agonist for gastrointestinal smooth muscle contraction.
|
-
-
- HY-P4805
-
-
-
- HY-U00136
-
-
-
- HY-106369
-
|
Potassium Channel
|
Cardiovascular Disease
|
HMR 1556, a chromanol derivative, is a potent IKs blocker with IC50s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively .
|
-
-
- HY-108564
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders .
|
-
-
- HY-P5072
-
|
Bombesin Receptor
|
Metabolic Disease
|
GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect .
|
-
-
- HY-118094
-
-
-
- HY-103148
-
|
5-HT Receptor
|
Neurological Disease
|
LY215840, a 5-HT7 receptor ligand and a 5-HT2 receptor antagonist, blocks serotonin-induced relaxation in canine coronary artery .
|
-
-
- HY-106908
-
WAY-PDA 641
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
WAY-PDA 641 is a potent and preferential PDE-IV inhibitor, with an IC50 of 0.42 μM for canine trachealis PDE-IV. WAY-PDA 641 induces respiratory muscle relaxation and bronchodilation .
|
-
-
- HY-10299
-
GSK-923295
Maximum Cited Publications
32 Publications Verification
|
Kinesin
Apoptosis
|
Cancer
|
GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.
|
-
-
- HY-103547
-
|
GCGR
|
Metabolic Disease
|
L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .
|
-
-
- HY-153168
-
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart
failure research .
|
-
-
- HY-113042
-
|
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw .
|
-
-
- HY-P3117
-
Pituitary adenylate cyclase-activating peptide (6-27)
|
Adenylate Cyclase
|
Neurological Disease
|
PACAP (6-27) (human, ovine, rat) is a PACAP receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases .
|
-
-
- HY-B0391
-
KT-611; BM-15275
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .
|
-
-
- HY-B0391A
-
KT-611 dihydrochloride; BM-15275 dihydrochloride
|
Adrenergic Receptor
|
Cancer
|
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia .
|
-
-
- HY-B0391B
-
KT-611 hydrochloride; BM-15275 hydrochloride
|
Adrenergic Receptor
|
Cancer
|
Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia .
|
-
-
- HY-B0391R
-
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
Naftopidil (Standard) is the analytical standard of Naftopidil. This product is intended for research and analytical applications. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .
|
-
-
- HY-P99820
-
NV-01
|
TNF Receptor
|
Inflammation/Immunology
|
Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
|
-
-
- HY-N0158
-
|
TGF-beta/Smad
Apoptosis
|
Infection
Inflammation/Immunology
Cancer
|
Oxymatrine, an alkaloid from Sophora flavescens Alt. with anti-inflammatory, antifibrosis, and antitumor effects, inhibits the iNOS expression and TGF-β/Smad pathway. Oxymatrine inhibits bocavirus minute virus of canines (MVC) replication, reduces viral gene expression and decreases apoptosis induced by viral infection.
|
-
-
- HY-15790A
-
A 3309 hydrate; AZD 7806 hydrate
|
Apical Sodium-Dependent Bile Acid Transporter
|
Metabolic Disease
|
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research .
|
-
-
- HY-15790R
-
-
-
- HY-B0335
-
GEA 6414
|
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
-
- HY-15970
-
KPT-335
|
CRM1
|
Cancer
|
Verdinexor(KPT-335) is a novel, orally bioavailable selective inhibitor of nuclear export (SINE), inhibits nuclear export protein Exportin 1(XPO1/CRM1) against canine tumor cell lines; also reduce influenza virus replication in vitro and in vivo.
|
-
-
- HY-17623
-
CJ-12420; RQ-00000004
|
Proton Pump
|
Metabolic Disease
|
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
|
-
-
- HY-10330
-
SU11654; PHA 291639E
|
PDGFR
VEGFR
c-Kit
|
Cancer
|
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
|
-
-
- HY-10330A
-
SU11654 phosphate; PHA 291639E phosphate
|
PDGFR
VEGFR
c-Kit
|
Cancer
|
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
|
-
-
- HY-110199
-
|
TRP Channel
|
Neurological Disease
|
TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models .
|
-
-
- HY-114822
-
PGA3
|
Prostaglandin Receptor
PPAR
|
Endocrinology
|
Prostaglandin A3 is a non-enzymatic dehydration product of prostaglandin E3 (PGE3). Prostaglandin A3 showed good affinity for canine EP2 and EP4 receptors with IC50 values of 120 and 20 nM, respectively. The Ki value of Prostaglandin A3 for human PPARγ was 188 μM .
|
-
-
- HY-147384
-
|
Calcium Channel
|
Cardiovascular Disease
|
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca 2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure .
|
-
-
- HY-N9019
-
|
Influenza Virus
|
Infection
|
1,4-Epidioxybisabola-2,10-dien-9-one is a 1,4-epidioxy-bisabola-2,12-diene derivate, which can be isolated from Curcuma longa L. 1,4-Epidioxybisabola-2,10-dien-9-one exhibits antiviral activity against influenza virus A/PR/8/34 (H1N1) in the MDCK cell line with an IC50 of 16.79 ± 4.03 μg/mL .
|
-
-
- HY-B0335S1
-
GEA 6414-13C6
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic acid- 13C6 is the 13C6 labeled Tolfenamic acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
-
- HY-13100
-
|
Proton Pump
|
Metabolic Disease
|
PF 03716556 is a potent, selective, competitive and reversible acid pump (H +,K +-ATPase) antagonist with pIC50s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H +,K +-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .
|
-
-
- HY-17623D
-
CJ-12420 Benzoate; RQ-00000004 Benzoate
|
Proton Pump
|
Metabolic Disease
|
Tegoprazan Benzoate is the benzoate form of Tegoprazan (HY-17623). Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
|
-
-
- HY-B0335S
-
|
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic acid-d4 is the deuterium labeled Tolfenamic Acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1[1][2].
|
-
-
- HY-10330S
-
|
Isotope-Labeled Compounds
PDGFR
VEGFR
c-Kit
|
Cancer
|
Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
|
-
- HY-B0335R
-
GEA 6414 (Standard)
|
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic Acid (Standard) is the analytical standard of Tolfenamic Acid. This product is intended for research and analytical applications. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
- HY-17623R
-
|
Proton Pump
|
Metabolic Disease
|
Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
|
-
- HY-15790
-
-
- HY-118830
-
DK-PGD2; 15-Oxo-13,14-dihydro-PGD2; 13,14-Dihydro-15-keto-PGD2
|
Prostaglandin Receptor
|
Endocrinology
|
13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation .
|
-
- HY-14850
-
Netazepide; YF 476; YM-220
|
Cholecystokinin Receptor
|
Metabolic Disease
Endocrinology
|
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively .
|
-
- HY-108586
-
|
Potassium Channel
|
Neurological Disease
|
NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels .
|
-
- HY-A0234
-
Prostenoglycine; TTPG; Tiase
|
Others
|
Endocrinology
|
Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
|
-
- HY-A0234R
-
|
Others
|
Endocrinology
|
Stepronin (Standard) is the analytical standard of Stepronin. This product is intended for research and analytical applications. Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
|
-
- HY-161524
-
|
HDAC
|
Cancer
|
HDAC6-IN-43 (compound 26) is a potent HDAC inhibitor. HDAC6-IN-43 effectively inhibits several HDACs, notably HDAC1, HDAC2, and HDAC6 (IC50 < 150 nM), displaying a particularly high sensitivity towards HDAC6 (IC50 = 11 nM). HDAC6-IN-43 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
|
-
- HY-12403A
-
TXA127 acetate; Angiotensin (1-7) (acetate); Ang-(1-7) (acetate)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
|
-
- HY-12403
-
TXA127; Angiotensin (1-7); Ang-(1-7)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-138961
-
|
Syk
|
Inflammation/Immunology
|
ER-27319, an acridone derivative, is a potent and selective SYK inhibitor, and inhibits the tyrosine phosphorylation of SYK and its activity. ER-27319 inhibits the release of antigen-induced allergic mediators from human and rat mast cells with an IC50 of 10 μM and can be used for study in allergic diseases .
|
-
- HY-108489
-
|
Syk
|
Inflammation/Immunology
|
ER-27319 (maleate), an acridone derivative, is a potent and selective SKY inhibitor, and inhibits the tyrosine phosphorylation of SYK and its activity. ER-27319 (maleate) inhibits the release of antigen-induced allergic mediators from human and rat mast cells with an IC50 of 10 μM and can be used for study in allergic diseases [1] [2] .
|
-
- HY-130229
-
(±)5,6-DiHETrE lactone
|
Others
|
Cardiovascular Disease
|
5,6-DiHET lactone ((±)5,6-DiHETrE lactone) is a lactonized form of 5,6-EET and 5,6-DiHET. In solution, 5(6)-EET degrades into 5(6)-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS.1 5,6-DiHET potently induces vasodilation of isolated canine coronary arterioles, with 41 and 100% inhibition occurring at 0.01 and 100 pM, respectively. It also induces vasodilation in isolated human microvessels and increases intracellular calcium levels in a dose-dependent manner, an effect that can be blocked by the nitric oxide scavenger L-NAME.
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1541
-
Motilin (canine)
|
Motilin Receptor
|
Metabolic Disease
|
Motilin, canine is a 22-amino acid peptide. Motilin is a potent agonist for gastrointestinal smooth muscle contraction.
|
-
- HY-P1784
-
|
Secretin Receptor
|
Endocrinology
|
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .
|
-
- HY-P4805
-
-
- HY-P3763
-
|
Peptides
|
Cardiovascular Disease
|
Atrial Natriuretic Peptide (7-28), human, canine is a peptide fragment of atrial natriuretic peptide, can be used as a peptide tag .
|
-
- HY-P5072
-
|
Bombesin Receptor
|
Metabolic Disease
|
GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect .
|
-
- HY-P3973
-
|
Peptides
|
Others
|
Thrombostatin cont-1 is an analogue of thrombostatin, which is a a bradykinin metabolite. Thrombostatin could decrease platelet activation in the canine carotid artery model of balloon angioplasty (BA) injury .
|
-
- HY-P0207
-
Endothelin-2 (human, canine); Human endothelin-2
|
Peptides
|
Cardiovascular Disease
Cancer
|
Endothelin-2 (49-69), human (Endothelin-2 (human, canine)) is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, ET-RA and ET-RB.
|
-
- HY-P0207A
-
Endothelin-2 (49-69) (human, canine) TFA; Human endothelin-2 TFA
|
Peptides
|
Cardiovascular Disease
Cancer
|
Endothelin-2 (49-69), human (TFA) (Endothelin-2 (49-69) (human, canine) (TFA)) is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, ET-RA and ET-RB.
|
-
- HY-P3117
-
Pituitary adenylate cyclase-activating peptide (6-27)
|
Adenylate Cyclase
|
Neurological Disease
|
PACAP (6-27) (human, ovine, rat) is a PACAP receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases .
|
-
- HY-P4714
-
|
Peptides
|
Others
|
(Tyr27)-α-CGRP (27-37) (canine, mouse, rat) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P4079
-
-
- HY-12403A
-
TXA127 acetate; Angiotensin (1-7) (acetate); Ang-(1-7) (acetate)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
|
-
- HY-12403
-
TXA127; Angiotensin (1-7); Ang-(1-7)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99483
-
AT 004; VT 007
|
CD20
|
Cancer
|
Blontuvetmab (AT 004)is a caninized CD20 monoclonal antibody. Blontuvetmab can be used for the research of Canine B-cell lymphoma .
|
-
- HY-P99301
-
Anti-Canine IL31 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
|
-
- HY-P99677
-
-
- HY-P990274
-
|
Inhibitory Antibodies
|
Others
|
Anti-Canine CD34 Antibody (1H6) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine CD34.
|
-
- HY-P990114
-
|
Inhibitory Antibodies
|
Others
|
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine PD-L1/B7-H1.
|
-
- HY-P99606
-
ZTS-00521426
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .
|
-
- HY-P99641
-
|
PD-1/PD-L1
|
Cancer
|
Gilvetmab is a potent caninized antiPD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .
|
-
- HY-P99438
-
KIND-030
|
Inhibitory Antibodies
|
Infection
|
Anivovetmab (KIND-030) is an anti-VP2 (parvovirus major capsid protein) monoclonal antibody (IgG2 type). Anivovetmab has the potential to study canine parvovirus infection.
|
-
- HY-P99297
-
ZTS-00508841
|
Trk Receptor
|
Inflammation/Immunology
|
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
|
-
- HY-P990107
-
-
- HY-P99579
-
AT-005; AT005
|
Inhibitory Antibodies
|
Cancer
|
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .
|
-
- HY-P99820
-
NV-01
|
TNF Receptor
|
Inflammation/Immunology
|
Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0335S1
-
|
Tolfenamic acid- 13C6 is the 13C6 labeled Tolfenamic acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
-
- HY-B0335S
-
|
Tolfenamic acid-d4 is the deuterium labeled Tolfenamic Acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1[1][2].
|
-
-
- HY-10330S
-
|
Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: